Compare RDNT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | APGE |
|---|---|---|
| Founded | 1985 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.7B |
| IPO Year | 1996 | 2023 |
| Metric | RDNT | APGE |
|---|---|---|
| Price | $72.39 | $134.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $82.80 | ★ $109.67 |
| AVG Volume (30 Days) | 645.3K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,616,630,000.00 | N/A |
| Revenue This Year | $22.78 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $50.82 | $34.40 |
| 52 Week High | $85.84 | $134.58 |
| Indicator | RDNT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 62.91 | 79.55 |
| Support Level | $64.71 | $80.52 |
| Resistance Level | $71.79 | N/A |
| Average True Range (ATR) | 2.69 | 0.25 |
| MACD | 0.50 | -1.37 |
| Stochastic Oscillator | 86.53 | 84.21 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.